Your AI-Trained Oncology Knowledge Connection!
In addition to endeavors to develop new therapeutics, we should anticipate and prioritize studies that will address questions regarding the efficacy of combination therapy, timing and sequencing strategies, and the development of predictive markers to individualize and optimize therapy.
We are seeing a new era in drug development with the identification of novel intra- and extracellular targets to which therapies are being directed. Perhaps more exciting is learning how to optimize standard therapies in combination with biologic agents and radiopharmaceuticals in order to target multiple pathways in prostate cancer growth. Stay tuned!
TALK NERDY TO US TAKE OUR TECH SURVEY FOR A CHANCE AT $500! What are physicians saying, thinking - and doing - when it comes to implementing office technologies? Help us to help you find out by completing our easy survey. We are working with our sister site, PhysiciansPractice.com, to learn all about it -- and we're willing to pay. Just go to the 2012 Tech Survey to complete our easy survey, and enter to win a $500 Visa gift card. It only takes five minutes. The contest will run through February 29th. No purchase is necessary. Void where prohibited. See official rules for full details, available here. Thank you for your participation!
The episode-of-care project is the first program in which a payer has partnered with the oncology community to reduce costs while paying for the demanding and complex cognitive work of the medical oncologist. The episode-of-care payment system seems to be working smoothly and we have not experienced the same erosion of our income that we have seen with other payers.
CancerNetwork presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. Check back for an interview with Andrew Evens, DO, MSc, on the oral abstract he's presenting at the meeting called "Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis." Dr. Evens is the deputy director for clinical and translational research and medical director of the Clinical Research Office at the UMass Memorial Health Care Cancer Center of Excellence.
As insurers, clinicians and the U.S. government attempt to slow the increasing rise of health care costs, many experts have identified the tool entitled “clinical pathways” as a solution. Oncologists who adhere to such pathways are thought to improve patient care and reduce expenses.
n their article, Dennis et al call for timely integration of palliative care into standard oncology care and sustained collaboration between these two specialties, to provide comprehensive, individualized care for patients with advanced, incurable cancer and their families.[
Authors von Gunten, Lutz, and Ferris have provided oncologists, and all physicians with patients who have cancer, an excellent and pithy review of how those with very advanced cancer are currently cared for as they approach the end-of-life
This article will review the overlap between palliative care and oncology and discuss the available evidence that true integration of palliative and oncology care provides patients with optimal oncology care.
Patients with advanced progressive cancer require care plans that address their physical, emotional, and psychosocial needs, as well as their goals of care.
In this article, prognostic data are summarized and a suggested approach for discussing hospice enrollment with patients is presented.
CancerNetwork presents exclusive coverage from the annual San Antonio Breast Cancer Symposium. As part of our preconference coverage, we present an interview with Dr. Kent Osborne, director of the Lester and Sue Smith Breast Cancer Center and the Dan L. Duncan Cancer Center at the Baylor College of Medicine, where he is also a professor of medicine in cellular and structural biology. Dr. Osborne is the moderator of the year in review session and he has been involved with the meeting since its beginning.Check back here for news and updates to come.
The article by Aneja, Gross, Soulos, and Yu outlines applications of geographical information systems (GIS) software to oncology research.
Flax, an annual plant believed to have originated in Egypt, is cultivated around internationally and is among the world’s oldest crops.
This review describes the development and technical capabilities of GIS, potential applications of Geographical Informational Systems in cancer research, and the limitations of such work.
This article summarizes some of the most important federal coverage provisions and safeguards that promote access to preventive services for individuals with cancer or individuals who are at risk for cancer
The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma.
Oncologist Compensation 2011Is your compensation keeping pace with that of your fellow oncologists? We surveyed practicing oncologists all across the country about their compensation and overall health of their practices. See what they said, then join the conversation about how your practice is different. View results from the 2011 Compensation Survey in our slideshow.
The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma, with particular focus on proteasome inhibitors and immunomodulatory drugs, along with other emerging agents (eg, histone deacetylase inhibitors, heat shock protein inhibitors, and monoclonal antibodies). As the treatment landscape has evolved, it has become readily apparent that the available therapies have different tolerability profiles depending on patient and disease characteristics.
The Future of Treatment for Patients With Relapsed/Refractory Multiple MyelomaThe supplement and associated publication costs were funded by Onyx Pharmaceuticals
A study has been released that demonstrates the cost-effectiveness of Medicare-funded cancer care treatment programs.
Find out how your compensation, bonuses, and benefits compare to your peers. Data exclusive to CancerNetwork.
Conference Calendar for Fall 2011 - Spring 2012
Counseling women at high risk for ovarian and uterine cancer is a complex process, from genetic diagnosisto the management of at-risk women. Rimes andcolleagues have presented these challenging issues, andsuggested ways to manage them, very well.
Coenzyme Q10, or CoQ10, is a naturally occurring, lipid-soluble antioxidant and an essential electron carrier involved in the mitochondrial respiratory chain. In mitochondria, CoQ10 functions as a coenzyme that assists in the oxidative phosphorylation of nutrients, leading to production of cellular adenosine triphosphate (ATP), or energy.
During the 1970s and 80s, several researchers in Canada and in the United States, including those at the National Cancer Institute, studied Essiac. All failed to find any evidence of effectiveness.
Women with high-grade serous ovarian cancer who also harbor a BRCA2, but not a BRCA1 mutation tend to have a better chemotherapy response and overall survival compared with those patients who are BRCA wild type.
Based on a review of prostate cancer treatment and screening trials, the U.S. Preventive Services Task Force (USPSTF) has stated that prostate-specific antigen (PSA)–based screening may not be necessary, saying that the potential benefits of the screening do not outweigh the potential harm of complications from evaluations and treatments.
I believe cancer doctors have a duty to be accessible to patients as much as possible. Taking treatment for cancer is to say the least an intense experience, sometimes an ordeal, and oncologists must be diligent in keeping everyone up to date on test results, logistics, complications, on good news as well as bad.
A recent epidemiology study by the NCI has found an almost four-fold increase of cancer survivors since 1971: 11.9 million in 2008 compared with 3 million in 1971, and the authors of the study expect a 42% increase in the number of older adult survivors in the next 10 years.
